Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases (vol 18, 1198, 2018)

被引：3

作者：

Tan, Wan-Ling ^{[1
]}

Ng, Quan Sing ^{[1
]}

Lim, Cindy ^{[2
]}

Tan, Eng Huat ^{[1
]}

Toh, Chee Keong ^{[1
]}

Ang, Mei-Kim ^{[1
]}

Kanesvaran, Ravindran ^{[1
]}

Jain, Amit ^{[1
]}

Tan, Daniel S. W. ^{[1
,3
]}

Lim, Darren Wan-Teck ^{[1
,4
]}

机构：

[1] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[2] Natl Canc Ctr Singapore, Clin Trials & Epidemiol Sci, Singapore, Singapore

[3] ASTAR, Genome Inst Singapore, Singapore, Singapore

[4] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore

来源：

BMC CANCER | 2018年 / 18卷

关键词：

D O I：

10.1186/s12885-018-5215-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ᅟ

引用

页数：2

共 50 条

[31] Response to afatinib in treatment-naive patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases (vol 18, pg 81, 2018)
Li, S. H.
Liu, C. Y.
Hsu, P. C.
Fang, Y. F.
Wang, C. C.
Kao, K. C.
Tseng, L. C.
Yang, C. T.
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 1 - 1
[32] Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Ballard, Peter
Yates, James W. T.
Yang, Zhenfan
Kim, Dong-Wan
Yang, James Chih-Hsin
Cantarini, Mireille
Pickup, Kathryn
Jordan, Angela
Hickey, Mike
Grist, Matthew
Box, Matthew
Johnstrom, Peter
Varnas, Katarina
Malmquist, Jonas
Thress, Kenneth S.
Janne, Pasi A.
Cross, Darren
[J]. CLINICAL CANCER RESEARCH, 2016, 22 (20) : 5130 - 5140
[33] A Phase IIIb Trial of Afatinib in EGFRm plus NSCLC: Analyses of Outcomes in Patients with Brain Metastases or Dose Reductions
Wu, Y.
Tu, H.
Feng, J.
Shi, M.
Zhao, J.
Wang, Y.
Chang, J.
Wang, J.
Cheng, Y.
Zhu, J.
Tan, E.
Li, K.
Zhang, Y.
Lee, V.
Yang, C.
Su, W.
Lam, D. C.
Srinivasa, B.
Rajappa, S.
Ho, C.
Lam, K. C.
Hu, Y.
Bondarde, S. A.
Liu, X.
Huang, D. C.
Wang, Y.
Pang, K.
Zhou, C.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S501 - S501
[34] Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases
Li, Wenqian
Bai, Rilan
Qian, Lei
Chen, Naifei
Zhao, Yuguang
Han, Fujun
Bai, Ling
Li, Jiaxuan
Yu, Yu
Cui, Jiuwei
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (02) : E40 - E47
[35] Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
Li, Changhui
Guo, Jindong
Zhao, Lei
Hu, Fang
Nie, Wei
Wang, Huimin
Zheng, Xiaoxuan
Shen, Yinchen
Gu, Ping
Zhang, Yujun
Zhang, Xueyan
[J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 3433 - 3443
[36] Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
Li, C.
Guo, J.
Zhao, L.
Hu, F.
Nie, W.
Wang, H.
Zheng, X.
Shen, Y.
Gu, P.
Zhang, Y.
Zhang, X.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[37] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases
Jiang, T.
Zhou, C.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[38] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
Jiang, Tao
Zhang, Yongchang
Li, Xuefei
Zhao, Chao
Chen, Xiaoxia
Su, Chunxia
Ren, Shengxiang
Yang, Nong
Zhou, Caicun
[J]. EUROPEAN JOURNAL OF CANCER, 2019, 121 : 98 - 108
[39] Aumolertinib in Treatment-Naive EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY
Wang, H.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S397 - S398
[40] Plasma microRNA signatures to predict EGFR-TKI resistance in EGFR-mutant advanced NSCLC patients.
Wang, Shuhang
Wang, Jie
Bai, Hua
An, Tongtong
Zhao, Jun
Wang, Zhijie
Duan, Jianchun
Zhuo, Minglei
Wang, Yuyan
Wu, Meina
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →